Annual EBITDA
-$25.39 M
+$3.08 M+10.83%
31 December 2023
Summary:
Chemomab Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$25.39 million, with the most recent change of +$3.08 million (+10.83%) on 31 December 2023. During the last 3 years, it has fallen by -$19.44 million (-326.90%). CMMB annual EBITDA is now -326.90% below its all-time high of -$5.95 million, reached on 31 December 2020.CMMB EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$3.71 M
+$58.00 K+1.54%
01 September 2024
Summary:
Chemomab Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$3.71 million, with the most recent change of +$58.00 thousand (+1.54%) on 01 September 2024. Over the past year, it has increased by +$657.00 thousand (+15.04%). CMMB quarterly EBITDA is now -238.50% below its all-time high of -$1.10 million, reached on 30 June 2020.CMMB Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$15.37 M
+$657.00 K+4.10%
01 September 2024
Summary:
Chemomab Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$15.37 million, with the most recent change of +$657.00 thousand (+4.10%) on 01 September 2024. Over the past year, it has increased by +$14.83 million (+49.10%). CMMB TTM EBITDA is now -804.89% below its all-time high of -$1.70 million, reached on 31 March 2020.CMMB TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CMMB EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +10.8% | +15.0% | +49.1% |
| 3 y3 years | -326.9% | -28.7% | -66.1% |
| 5 y5 years | - | - | - |
CMMB EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -326.9% | +10.8% | -28.7% | +58.9% | -66.1% | +55.0% |
| 5 y | 5 years | -326.9% | +10.8% | -238.5% | +58.9% | -804.9% | +55.0% |
| alltime | all time | -326.9% | +10.8% | -238.5% | +58.9% | -804.9% | +55.0% |
Chemomab Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3.71 M(-1.5%) | -$15.37 M(-4.1%) |
| June 2024 | - | -$3.77 M(-6.9%) | -$16.03 M(-21.6%) |
| Mar 2024 | - | -$4.05 M(+5.2%) | -$20.44 M(-19.6%) |
| Dec 2023 | -$25.39 M(-10.8%) | -$3.85 M(-11.9%) | -$25.43 M(-15.8%) |
| Sept 2023 | - | -$4.37 M(-46.6%) | -$30.21 M(-11.5%) |
| June 2023 | - | -$8.18 M(-9.5%) | -$34.14 M(+6.0%) |
| Mar 2023 | - | -$9.03 M(+4.7%) | -$32.20 M(+13.1%) |
| Dec 2022 | -$28.48 M | -$8.63 M(+4.0%) | -$28.48 M(+14.5%) |
| Sept 2022 | - | -$8.30 M(+33.0%) | -$24.86 M(+27.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2022 | - | -$6.24 M(+17.6%) | -$19.44 M(+21.9%) |
| Mar 2022 | - | -$5.31 M(+5.9%) | -$15.95 M(+29.3%) |
| Dec 2021 | -$12.33 M(+107.3%) | -$5.01 M(+73.9%) | -$12.33 M(+33.2%) |
| Sept 2021 | - | -$2.88 M(+5.0%) | -$9.26 M(+21.9%) |
| June 2021 | - | -$2.75 M(+62.3%) | -$7.59 M(+27.8%) |
| Mar 2021 | - | -$1.69 M(-12.6%) | -$5.94 M(-0.1%) |
| Dec 2020 | -$5.95 M | -$1.94 M(+59.1%) | -$5.95 M(+48.3%) |
| Sept 2020 | - | -$1.22 M(+11.0%) | -$4.01 M(+43.5%) |
| June 2020 | - | -$1.10 M(-35.5%) | -$2.79 M(+64.5%) |
| Mar 2020 | - | -$1.70 M | -$1.70 M |
FAQ
- What is Chemomab Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Chemomab Therapeutics?
- What is Chemomab Therapeutics annual EBITDA year-on-year change?
- What is Chemomab Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Chemomab Therapeutics?
- What is Chemomab Therapeutics quarterly EBITDA year-on-year change?
- What is Chemomab Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Chemomab Therapeutics?
- What is Chemomab Therapeutics TTM EBITDA year-on-year change?
What is Chemomab Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of CMMB is -$25.39 M
What is the all time high annual EBITDA for Chemomab Therapeutics?
Chemomab Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$5.95 M
What is Chemomab Therapeutics annual EBITDA year-on-year change?
Over the past year, CMMB annual earnings before interest, taxes, depreciation & amortization has changed by +$3.08 M (+10.83%)
What is Chemomab Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of CMMB is -$3.71 M
What is the all time high quarterly EBITDA for Chemomab Therapeutics?
Chemomab Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$1.10 M
What is Chemomab Therapeutics quarterly EBITDA year-on-year change?
Over the past year, CMMB quarterly earnings before interest, taxes, depreciation & amortization has changed by +$657.00 K (+15.04%)
What is Chemomab Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of CMMB is -$15.37 M
What is the all time high TTM EBITDA for Chemomab Therapeutics?
Chemomab Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$1.70 M
What is Chemomab Therapeutics TTM EBITDA year-on-year change?
Over the past year, CMMB TTM earnings before interest, taxes, depreciation & amortization has changed by +$14.83 M (+49.10%)